Literature DB >> 1965109

Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats.

P R Wyde1, M W Ambrose, H L Meyer, C L Zolinski, B E Gilbert.   

Abstract

The toxicity and antiviral efficacy of carbocyclic 3-deazaadenosine (Cc3Ado) against respiratory syncytial (RSV) and parainfluenza type 3 (PIV3) virus infections were tested in tissue culture and in cotton rats. The mean median efficacious dose (ED50) of Cc3Ado in HEp2 cells against RSV and PIV3 was 9 and 14 micrograms/ml, respectively. These values were 85- and 55-fold less than the median inhibitory (toxic) dose (ID50) of Cc3Ado in this cell line (750 micrograms/ml), and similar to values obtained for ribavirin. Cc3Ado exhibited no significant antiviral activity against influenza A, influenza B, adeno type 5 or adeno type 7 viruses (all ED50 were greater than 1000 micrograms/ml). In cotton rats, animals given greater than or equal to 1 mg/kg/day Cc3Ado intraperitoneally on days 1, 2 and 3 after experimental challenge with virus, consistently had significant reductions in pulmonary RSV and PIV3 titers compared to pulmonary virus titers in comparably treated control animals. The minimum efficacious dose of ribavirin given under the same conditions was 30 mg/kg/day. Cc3Ado was also efficacious in cotton rats when given orally by gavage, or when different administration schedules were used. The median efficacious dose of Cc3Ado when given orally was 10 mg/kg/day. No significant toxic effects were noted in cotton rats, even in animals given 20 mg/kg daily for eight consecutive days.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1965109     DOI: 10.1016/0166-3542(90)90003-p

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  9 in total

Review 1.  Viral Epitranscriptomics.

Authors:  Edward M Kennedy; David G Courtney; Kevin Tsai; Bryan R Cullen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

2.  Epitranscriptomic Enhancement of Influenza A Virus Gene Expression and Replication.

Authors:  David G Courtney; Edward M Kennedy; Rebekah E Dumm; Hal P Bogerd; Kevin Tsai; Nicholas S Heaton; Bryan R Cullen
Journal:  Cell Host Microbe       Date:  2017-09-13       Impact factor: 21.023

3.  Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses.

Authors:  S Shigeta; S Mori; M Baba; M Ito; K Honzumi; K Nakamura; H Oshitani; Y Numazaki; A Matsuda; T Obara
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 4.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

5.  Addition of m6A to SV40 late mRNAs enhances viral structural gene expression and replication.

Authors:  Kevin Tsai; David G Courtney; Bryan R Cullen
Journal:  PLoS Pathog       Date:  2018-02-15       Impact factor: 6.823

Review 6.  Epitranscriptomic(N6-methyladenosine) Modification of Viral RNA and Virus-Host Interactions.

Authors:  Hasan Imam; Geon-Woo Kim; Aleem Siddiqui
Journal:  Front Cell Infect Microbiol       Date:  2020-11-24       Impact factor: 5.293

7.  N6-methyladenosine RNA modification (m6A) is of prognostic value in HPV-dependent vulvar squamous cell carcinoma.

Authors:  Mateja Condic; Thore Thiesler; Christian Staerk; Niklas Klümper; Jörg Ellinger; Eva K Egger; Kirsten Kübler; Glen Kristiansen; Alexander Mustea; Damian J Ralser
Journal:  BMC Cancer       Date:  2022-09-01       Impact factor: 4.638

Review 8.  Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology.

Authors:  Jiahua Lu; Junjie Qian; Shengyong Yin; Lin Zhou; Shusen Zheng; Wu Zhang
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244

Review 9.  Epigenetic and epitranscriptomic regulation of viral replication.

Authors:  Kevin Tsai; Bryan R Cullen
Journal:  Nat Rev Microbiol       Date:  2020-06-12       Impact factor: 60.633

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.